Search Result

Results for "

GLUT1 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (43) Akt (3) AMPK (2) Amylases (2) Apoptosis (12) Autophagy (4) Bacterial (1) Bcl-2 Family (1) Caspase (2) COX (2) Disulfidptosis (3) E1/E2/E3 Enzyme (1) EGFR (2) Endogenous Metabolite (4) Epigenetic Reader Domain (1) ERK (1) FABP (1) FAK (1) FAP (1) Fungal (1) HDAC (1) Hexokinase (1) HIV (1) HIV Integrase (1) HSP (1) IAP (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (1) Lactate Dehydrogenase (1) MDM-2/p53 (1) Mitophagy (1) Monoamine Oxidase (1) mTOR (2) NF-κB (3) PARP (1) PERK (1) Phosphatase (1) PI3K (2) PIN1 (1) PROTACs (1) Reactive Oxygen Species (ROS) (3) Reference Standards (6) SGLT (2) Sirtuin (2) SOD (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) Topoisomerase (1) Tyrosinase (1) VEGFR (1) Virus Protease (2)
By Research Areas:	Cancer (35) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (8) Metabolic Disease (17) Neurological Disease (4)

By Targets:

GLUT (43)

Akt (3)

AMPK (2)

Amylases (2)

Apoptosis (12)

Autophagy (4)

Bacterial (1)

Bcl-2 Family (1)

Caspase (2)

COX (2)

Disulfidptosis (3)

E1/E2/E3 Enzyme (1)

EGFR (2)

Endogenous Metabolite (4)

Epigenetic Reader Domain (1)

ERK (1)

FABP (1)

FAK (1)

FAP (1)

Fungal (1)

HDAC (1)

Hexokinase (1)

HIV (1)

HIV Integrase (1)

HSP (1)

IAP (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JNK (1)

Lactate Dehydrogenase (1)

MDM-2/p53 (1)

Mitophagy (1)

Monoamine Oxidase (1)

mTOR (2)

NF-κB (3)

PARP (1)

PERK (1)

Phosphatase (1)

PI3K (2)

PIN1 (1)

PROTACs (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (6)

SGLT (2)

Sirtuin (2)

SOD (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (1)

Topoisomerase (1)

Tyrosinase (1)

VEGFR (1)

Virus Protease (2)

By Research Areas:

Cancer (35)

Cardiovascular Disease (3)

Infection (5)

Inflammation/Immunology (8)

Metabolic Disease (17)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: GLUT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100017

BAY-876 Maximum Cited Publications 52 Publications Verification	GLUT Disulfidptosis	Cancer
BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC₅₀ of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

HY-N0142

Phloretin Maximum Cited Publications 24 Publications Verification NSC 407292; RJC 02792	SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM，respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-145597

KL-11743 5 Publications Verification	GLUT Disulfidptosis	Metabolic Disease Cancer
KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC₅₀s of 115, 137, 90, and 68 nM for *GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors* to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

HY-N0002

(-)-Epicatechin gallate 5+ Cited Publications Epicatechin gallate; ECG; (-)-Epicatechin 3-O-gallate	COX Autophagy Virus Protease GLUT	Infection Cancer
(-)-Epicatechin gallate (Epicatechin gallate) inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 7.5 μM . (-)-Epicatechin gallate is a *GLUT1* and *GLUT5* inhibitor. (-)-Epicatechin gallate decreases cell growth of GLUT5-expressing hxt ⁰ yeast cells .

HY-19331

WZB117 20+ Cited Publications	GLUT	Cancer
WZB117 is a glucose transporter 1 (Glut1) inhibitor, which downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.

HY-N0668

Rubusoside 2 Publications Verification	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters *GLUT-1* and fructose *GLUT-5, and inhibits* NF-κB and α-amylase (α-amylase) .

HY-18728

STF-31 15+ Cited Publications	GLUT Autophagy	Cancer
STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC₅₀ of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .

HY-148983

Hydroxylamine (50% w/w in water) 1 Publications Verification	Monoamine Oxidase Bacterial GLUT	Infection Metabolic Disease Inflammation/Immunology
Hydroxylamine (50% w/w in water) is an inorganic highly reactive compound and antibacterial agent. Hydroxylamine (50% w/w in water) acutely activates the transport activity of *GLUT1, inhibits* Monoamine oxidase activity. Hydroxylamine (50% w/w in water) inhibits nitrite oxidizing bacteria. Hydroxylamine (50% w/w in water) activates glucose uptake. Hydroxylamine (50% w/w in water) can be used in the research of inflammatory diseases and allergies[1][2][3][4] .

HY-139605

GLUT inhibitor-1 1 Publications Verification	GLUT	Inflammation/Immunology Cancer
GLUT inhibitor-1 is a potent and orally active inhibitor of glucose transporters, targeting both *GLUT1* and *GLUT3, with IC₅₀s of 242 nM and 179 nM, respectively. GLUT* inhibitor-1 has the potential for the reaesrch of cancers and autoimmune diseases .

HY-W179181

MSNBA 1 Publications Verification	GLUT	Metabolic Disease Cancer
MSNBA is a potent and selective GLUT5 fructose transport inhibitor with an IC₅₀ of 0.10 mM. MSNBA does not affect the transport activity of human GLUT1, GLUT2, GLUT3, GLUT4 or bacterial GlcPSe. MSNBA competitively inhibits GLUT5 fructose uptake with a K_i of 3.2 μM in MCF7 cells. MSNBA can be used for the study of cancer or diabetes .

HY-101849

Fasentin 4 Publications Verification	GLUT TNF Receptor Apoptosis	Cardiovascular Disease Cancer
Fasentin, a potent glucose uptake inhibitor, inhibits *GLUT-1/GLUT-4* transporters. Fasentin preferentially inhibits GLUT4 (IC₅₀=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .

HY-175674

NGI-235	NF-κB Toll-like Receptor (TLR) GLUT	Inflammation/Immunology
NGI-235 is an STT3A-selective oligosaccharyltransferase complex OST-A inhibitor. NGI-235 preferentially inhibits OST-A catalytic activity, impairing N-glycosylation of OST-A substrates. NGI-235 causes the hypoglycosylation of both TLR4, *GLUT1* and inhibits NF-κB signaling. NGI-235 can be used for the research of inflammation .

HY-146980

GLUT4-IN-2	Apoptosis GLUT	Cancer
GLUT4-IN-2 is a potent and selective *GLUT4* inhibitor with IC₅₀s of 11.4 µM and 6.8 µM for GLUT1 and GLUT4, respectively. GLUT4-IN-2 induces cell apoptosis and cell cycle arrest at G0/G1phase. GLUT4-IN-2 shows potent antitumor activity .

HY-124113

4'-Bromo-resveratrol 4′‐BR	Sirtuin Apoptosis Caspase Lactate Dehydrogenase GLUT	Metabolic Disease Inflammation/Immunology Cancer
4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC₅₀ of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD ⁺/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma .

HY-148315

GLUT1-IN-2	GLUT	Infection
GLUT1-IN-2 (compound 17) is a *GLUT1* inhibitor with an IC₅₀ value of 12 μM. GLUT1-IN-2 shows inhibitory effect to Plasmodium falciparum hexose transporter PfHT with an IC₅₀ value of 13 μM. GLUT1-IN-2 can be used for the research of infection .

HY-N2445

Flavokawain C 4 Publications Verification	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK	Cancer
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins *GLUT1* and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-W176629

Hydrocotarnine 1 Publications Verification	E1/E2/E3 Enzyme Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology
Hydrocotarnine is a Cbl inhibitor, and results in inflammasome-mediated IL-18 secretion in colitis. Hydrocotarnine increases expression of GLUT1 and cellular glucose uptake in glycolytic metabolism. Hydrocotarnine acts as an agent that provides analgesic effect in cancer research .

HY-158302

Glutor	GLUT Apoptosis	Cancer
Glutor is a selective *GLUT 1/2/3* inhibitor that can suppress glucose uptake. Glutor can inhibit glycolysis and has anti-tumor activity, inducing cell apoptosis .

HY-N7676

Marein 3 Publications Verification	AMPK HDAC	Cardiovascular Disease Neurological Disease Metabolic Disease
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-108935

Lavendustin B	HIV Integrase GLUT Tyrosinase	Cancer
Lavendustin B is an inhibitor of HIV-1 integrase interaction with LEDGF/p75 with an IC₅₀ of 94.07 μM. Lavendustin B is an ATP-competitive *GLUT1* inhibitor with a K_i of 15 μM. Lavendustin B is also a weak inhibitor of tyrosine kinases .

HY-N7433

4,6-O-Ethylidene-α-D-glucose Ethylidene-glucose	GLUT Endogenous Metabolite	Metabolic Disease
4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a K_i of 12 mM for wild-type 2-deoxy-D-glucose transport .

HY-151486

GLUT1-IN-1	GLUT	Cancer
GLUT1-IN-1 is a glucose transporter 1 (GLUT1) inhibitor and has a GLUT1-specific inactivation ability. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC₅₀ values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer .

HY-N6924

Zingibroside R1 1 Publications Verification	HIV PIN1 Fungal GLUT Reactive Oxygen Species (ROS)	Infection Neurological Disease Metabolic Disease Cancer
Zingibroside R1 is an orally active triterpene saponin with multiple biological activities including antioxidant, anti-inflammatory, antiviral, and metabolic regulatory properties. Zingibroside R1 reduces the expression of PIN family members, inhibits the expression of PLT1/PLT2, WOX5, SHR, and SCR, disrupts auxin transport and distribution, triggers plant ROS responses, and inhibits root growth. Zingibroside R1 extends the lifespan of Caenorhabditis elegans, enhances its heat stress resistance, and improves its motor ability. Hydrogel derivatives of Zingibroside R1 inhibit the proliferation of Candida albicans by binding to its β-1,3-glucan and exhibit antifungal activity. Zingibroside R1 inhibits *GLUT1*-mediated uptake and alleviates liver injury. Zingibroside R1 can be used in research related to neurodegenerative diseases, vulvovaginal candidiasis, acute liver injury, Ehrlich ascites tumor and HIV-1 infection .

HY-121086

BAY-588	GLUT	Metabolic Disease
BAY-588 is a selective inhibitor of *GLUT1* with an IC₅₀ value of 1.18μM .

HY-158302A

(R)-Glutor	GLUT Apoptosis	Cancer
(R)-Glutor is the R-enantiomer of Glutor (HY-158302). Glutor is a selective *GLUT 1/2/3* inhibitor that can suppress glucose uptake. Glutor can inhibit glycolysis and has anti-tumor activity, inducing cell apoptosis .

HY-N0002R

(-)-Epicatechin gallate (Standard) 5+ Cited Publications Epicatechin gallate(Standard); ECG(Standard); (-)-Epicatechin 3-O-gallate (Standard)	Reference Standards COX Autophagy Virus Protease GLUT	Infection Cancer
(-)-Epicatechin gallate (Standard) is the analytical standard of (-)-Epicatechin gallate. This product is intended for research and analytical applications. (-)-Epicatechin gallate (Epicatechin gallate) inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 7.5 μM. (-)-Epicatechin gallate is a *GLUT1* and *GLUT5* inhibitor. (-)-Epicatechin gallate decreases cell growth of GLUT5-expressing hxt ⁰ yeast cells .

HY-161501

3-Fluoro-evodiamine glucose	GLUT Topoisomerase Apoptosis	Cancer
3-Fluoro-evodiamine glucose (Compound 8) is an evodiamine-glucose conjugate. 3-Fluoro-evodiamine glucose activates the expression of glucose transporter 1 (GLUT1), and inhibits topoisomerase I/II. 3-Fluoro-evodiamine glucose induces apoptosis and arrests the cell cycle at G2/M phase. 3-Fluoro-evodiamine glucose exhibits antitumor efficacy in vivo and in vitro, without significant toxicity .

HY-N0142R

Phloretin (Standard) Maximum Cited Publications 24 Publications Verification NSC 407292 (Standard); RJC 02792 (Standard)	Reference Standards SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-16605

SIRT6-IN-6	Sirtuin GLUT	Metabolic Disease
SIRT6-IN-6 (compound 6d) is a potent and selective SIRT6 inhibitor with an IC₅₀ of 4.93 μM and a K_i of ~10 μM. SIRT6-IN-6 shows selectivity against other members of the HDAC family (SIRT1-3 and HDAC1-11). SIRT6-IN-6 significantly increases the level of glucose transporter *GLUT-1*, thereby reducing blood glucose in a mouse model of type 2 diabetes. SIRT6-IN-6 can be used for type 2 diabetes research .

HY-18284

AS1938909	Akt GLUT Phosphatase	Others
AS1938909 is a compound that inhibits SHIP2 activity. It can selectively inhibit SHIP2, increase Akt phosphorylation, and regulate glucose metabolism. Its effect is related to upregulating GLUT1 gene expression.

HY-176050

Rapaglutin A RgA; JW11-D2	GLUT	Cancer
Rapaglutin A is a glucose transporter (GLUT) inhibitor. Rapaglutin A is a pan-GLUT inhibitor of Class I isoforms GLUT1, GLUT3, and GLUT4 with an IC₅₀ of 12 nM. Rapaglutin A has an inhibitory effect on A549 proliferation .

HY-N0668R

Rubusoside (Standard)	GLUT Amylases NF-κB Reference Standards	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-163726

GLUT1/EGFR-IN-1	GLUT EGFR Apoptosis	Cancer
GLUT1/EGFR-IN-1 (compound H) is a potent inhibitor of *GLUT1* and EGFR. GLUT1/EGFR-IN-1 can simultaneously act on the EGFR tyrosine kinase ATP-binding site and inhibit GLUT1-mediated energy metabolism, resulting in reductions in ATP, MMP, intra-cellular lactic acid, and EGFR nuclear transfer. GLUT1/EGFR-IN-1 can be used for nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC) research .

HY-175767

PROTAC BRD4 Degrader-39	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-39 is a selective targeting Bromodomain protein 4 (BRD4) degrader with an DC₅₀ value of 24.66 nM. PROTAC BRD4 Degrader-39 conjugates BRD PROTAC (ARV-771) (HY-100972) with carbohydrate. PROTAC BRD4 Degrader-39 selectively delivers to tumor cells with high GLUT1 expression, followed by GSH-triggered release of ARV-771 and degrades BRD4. PROTAC BRD4 Degrader-39 can inhibit tumor growth and show no significant toxicity. PROTAC BRD4 Degrader-39 can be used for the research of cancer, such as breast cancer . (Structure Note: Pink: BRD4 ligand (HY-78695); Blue: VHL ligand (HY-112078); Black: (HY-42427); BRD4 ligand-Linker: (HY-42429))

HY-163139

Physagulide Y	GLUT	Cancer
Physagulide Y (2), a withanolide with anticancer activity, is a *GLUT1* inhibitor .

HY-170313

GLUT-1-IN-4	GLUT Apoptosis Reactive Oxygen Species (ROS)	Cancer
GLUT-1-IN-4 (Compound 13) is the p53 protein-dependent inhibitor for GLUT-1 glucose transporter. GLUT-1-IN-4 inhibits the proliferation of multiple cancer cells with IC₅₀ in submicromolar levels. GLUT-1-IN-4 arrests the cell cycle, stimulates oxidative stress, and induces apoptosis .

HY-162132

WZB117-PPG	GLUT	Cancer
WZB117-PPG is a glucose transporter 1 (GLUT1) inhibitor with anticancer activity. WZB117-PPG has remarkable photolysis efficiency and cytotoxicity to cancer cells under visible light irradiation .

HY-N7433R

4,6-O-Ethylidene-α-D-glucose (Standard) Ethylidene-glucose (Standard)	Reference Standards GLUT Endogenous Metabolite	Metabolic Disease
4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a Ki of 12 mM for wild-type 2-deoxy-D-glucose transport .

HY-167857

(Rac)-Glutipyran	GLUT	Cancer
(Rac)-Glutipyran is a broad-spectrum *GLUT* inhibitor that targets both *GLUT1* and *GLUT3. (Rac)-Glutipyran inhibits* glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC₅₀=1.8 μM) and glucose uptake (IC₅₀=0.13 μM) .

HY-101849R

Fasentin (Standard)	Reference Standards GLUT TNF Receptor Apoptosis	Cardiovascular Disease Cancer
Fasentin (Standard) is the analytical standard of Fasentin. This product is intended for research and analytical applications. Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .

HY-167857S

Glutathione Disulfide-13C4,15N2	Isotope-Labeled Compounds GLUT	Cancer
Glutathione Disulfide- ¹³C₄, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled (Rac)-Glutipyran (HY-167857). (Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC₅₀=1.8 μM) and glucose uptake (IC₅₀=0.13 μM) .

HY-183069

FKL-137	GLUT PI3K Akt Apoptosis Bcl-2 Family	Cancer
FKL-137 is a *GLUT1* and PI3K/AKT signaling pathway inhibitor. FKL-137 binds to GLUT1, reduces glucose uptake and lactate secretion, downregulates glucose metabolism-related proteins, and inhibits erythroleukemia cell proliferation. FKL-137 downregulates PI3K, p-PI3K, AKT, p-AKT levels, disrupts the PI3K/AKT-GLUT1 positive feedback loop, and suppresses erythroleukemia cell proliferation. FKL-137 induces apoptosis via upregulated Bax, Cleaved-PARP and downregulated Bcl-2, PARP. FKL-137 can be used for the research of erythroleukemia .

HY-138976

NV-5440	mTOR GLUT	Neurological Disease Metabolic Disease Cancer
NV-5440 (Compound I-120) is an mTORC1 inhibitor and glucose transporter inhibitor. NV-5440 targets *GLUT-1, -2, -3, and -4, and shows no activity against GLUT-5. NV-5440 inhibits* glucose uptake .

HY-100017R

BAY-876 (Standard)	Reference Standards GLUT Disulfidptosis	Cancer
BAY-876 (Standard) is the analytical standard of BAY-876 (HY-100017). This product is intended for research and analytical applications. BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

HY-180805

HK2-IN-3	Hexokinase Mitophagy Apoptosis GLUT	Cancer
HK2-IN-3 (compound 12) is a potent hexokinase 2 (HK2) inhibitor with an IC₅₀ of 56.4 nM. HK2-IN-3 reduces glucose uptake and downregulated *GLUT1/GLUT4* in oral squamous cell carcinoma (OSCC). HK2-IN-3 induces mitophagy and apoptosis. HK2-IN-3 suppresses tumor growth and angiogenesis in OSCC xenograft mouse models. HK2-IN-3 can be used for OSCC research .

HY-182250

BR103354	FAP ERK GLUT	Metabolic Disease Inflammation/Immunology
BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC₅₀ value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and *Glut1* that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis .

Cat. No.	Product Name	Category	Target	Chemical Structure